Clinical Research Directory
Browse clinical research sites, groups, and studies.
Molecular Signatures in Inflammatory Skin Disease
Sponsor: Prof. Dr. Stephan Weidinger
Summary
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.
Official title: Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2017-01-20
Completion Date
2029-12-31
Last Updated
2025-07-22
Healthy Volunteers
No
Conditions
Interventions
Anti-TNF
Subject receives anti-TNF antibodies open-label as per guidelines
Anti-IL12/23
Subject receives anti-IL12/23 antibodies open-label as per guidelines
Anti-IL17
Subject receives anti-IL17 antibodies open-label as per guidelines
Dupilumab
Subject receives Dupilumab open-label as per guidelines
Anti-IL23
Subject receives anti-IL23 antibodies open-label as per guidelines
Baricitinib
Subject receives Baricitinib open-label as per guidelines
Abrocitinib
Subject receives Abrocitinib open-label as per guidelines
Upadacitinib
Subject receives Upadacitinib open-label as per guidelines
Tralokinumab
Subject receives Tralokinumab open-label as per guidelines
Lebrikizumab
Subject receives Lebrikizumab open-label as per guidelines
Nemolizumab
Subject receives Nemolizumab open-label as per guidelines
Locations (1)
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel
Kiel, Germany